What's Happening?
Arrakis Therapeutics, a biopharmaceutical company based in Waltham, Massachusetts, has announced the appointment of Mark DeLong as its new Chief Executive Officer, effective June 29, 2026. This leadership change follows the retirement of Michael Gilman,
PhD, who has had a distinguished 40-year career in the biotech industry. Dr. Gilman will continue to contribute to the company as Chairman of the Board, a position he assumes from Katrine Bosley, who is stepping down after seven years. Under Dr. Gilman's leadership, Arrakis has developed a pioneering platform for discovering small molecule medicines that target RNA, with a focus on treating myotonic dystrophy type 1 (DM1). Mark DeLong, who previously served as Chief Business & Strategy Officer at Apellis Pharmaceuticals, brings over 25 years of experience in the biopharmaceutical industry to his new role at Arrakis.
Why It's Important?
The transition in leadership at Arrakis Therapeutics is significant as the company is poised to advance its RNA-targeted small molecule drug candidate into clinical trials for DM1, a form of muscular dystrophy. This development represents a potential breakthrough in genetic medicine, offering a new approach to treating diseases at their genetic root. Mark DeLong's appointment is expected to drive the company's strategic goals forward, leveraging his extensive experience in business development and strategy. His previous role in the $5.6 billion acquisition of Apellis by Biogen highlights his capability to lead Arrakis through its next phase of growth. The successful development and commercialization of Arrakis' drug candidates could have a substantial impact on the biopharmaceutical industry, particularly in the field of RNA-targeted therapies.
What's Next?
As Arrakis transitions to a clinical-stage company, the focus will be on advancing its lead drug candidate for DM1 through clinical development. The company aims to leverage its RNA-targeted small molecule platform to develop additional genetic medicines. Stakeholders, including investors and the scientific community, will be closely monitoring the clinical trial outcomes and the company's ability to scale its operations. The leadership change may also prompt strategic partnerships or collaborations to enhance Arrakis' capabilities and market reach. The success of these initiatives could position Arrakis as a leader in the emerging field of RNA-targeted therapies.
